Sellas Life Sciences

NAQ:SLS · US81642T2096

BiotechnologySmall

360° View

Value42

Price/Sales24

Price/Earnings97

Price/Book3

Dividend Yield—

Growth69

Revenue Growth—

Profit Growth83

Capital Growth8

TSR 52w98

Safety82

Leverage77

Liquidity19

Refinancing83

Combined62

Sentiment47

Analyst Opinions26

Pro Holdings21

Opinion Changes50

Market Pulse87

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Employees18

Websitesellaslifesciences.com

ISINUS81642T2096

Last UpdateApr 2, 2026

Index & Theme

HematologyImmunologyVaccinesGenetic DisorderOncologyBiopharmaBiotechnology

Description

SELLAS Life Sciences Group, Inc. operates as a late-stage clinical biopharmaceutical company. The company focuses on the development of novel therapeutics for a broad range of cancer indications. The company’s product candidates include galinpepimut-…

Analysis

Sellas Life Sciences's 360° View rank of 62 places it above its peer average — better than 62% of its true peers.

It's growing solidly (69) and on the expensive side (42). On safety it is very well financed (82), and the market shows muted sentiment (47). Taken together, its Combined rank of 62 reads as above its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sellas Life Sciences with its peers

Incyte

NSQ:INCY

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Crescent Biopharma

NAQ:CBIO

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Celcuity

NAQ:CELC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

MacroGenics

NSQ:MGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Eupraxia Pharmaceuticals

TOR:EPRX

—

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →